
ECI Biotech Inc (AKA: Expressive Constructs Inc) Profile last edited on: 7/3/19
CAGE: 1WED0
UEI: W9ZMD225E7L3
Business Identifier: Detection of microbial pathogens and stabilizing active proteins to protect against infection. Is this YOUR Company?
Ensure accuracy and completeness of YOUR Company Profile by completing the brief Survey Instrument attached
Do you know about this Awardees?
Let us encourage you to provide any data which would enhance the completeness of this firm's profile.
Location Information
Location: Single
Congr. District: 02
County: Worcester
Congr. District: 02
County: Worcester
Public Profile
Expressive Constructs, Inc., doing business as ECI Biotech Inc., is structured around development of diagnostic sensors and therapeutics for detecting microbial pathogens and stabilizing active proteins to protect against infection. The firm offers a family of diagnostic sensors that identify signature enzyme targets and substrates using a combination of genomics and biochemical screening; and a family of proteins that prevent damage by blocking upstream mechanisms of pathogen induced apoptosis. With four areas of core competence: molecular biology, genomics, protein expression, and assay development, ECI products pipeline includes a diagnostic sensor for urinary tract infections and also wound care systems that provide early warning of emergent infections and promote healing. Products offered by the firm are incorporated into medical devices and into consumer products, as well as used as point of care diagnostic tools. The company's products are used in feminine care, wound care, oral care, vision care, food safety, and hospital infection control applications.
Extent of SBIR involvement
Synopsis: Awardee Business Condition
Employee Range
10-14Revenue Range
1M-1.5MVC funded?
YesPublic/Private
Privately HeldStock Info
----IP Holdings
5-9Awards Distribution by Agency
Most Recent SBIR Projects
Year | Phase | Agency | Total Amount | |
---|---|---|---|---|
2012 | 1 | NIH | $298,291 | |
Project Title: Rapid Detection Of Periprosthetic Joint Infection | ||||
2009 | 2 | NIH | $1,157,710 | |
Project Title: Novel Method to Detect Pathogens for the Diagnosis of Chronic Wound Infection | ||||
2008 | 2 | NIH | $299,066 | |
Project Title: Localized Delivery of a Novel Therapeutic Agent for Periodontal Disease | ||||
2008 | 1 | NIH | $200,870 | |
Project Title: Simple and Inexpensive Diagnostic Tools for Yeast Infections | ||||
2004 | 1 | NIH | $100,000 | |
Project Title: Protein Mediated Protection from Microbial Keratitis |
Key People / Management
Anthony J Bernardo -- Past CEO
Mitchell C Sanders -- CEO and Founder
Geert Cauwenbergh -- Executive Chairman
James Comolli
David Fogel -- CFO
Mitchell C Sanders -- CEO and Founder
Geert Cauwenbergh -- Executive Chairman
James Comolli
David Fogel -- CFO
Company News
Jul
01
2012
|
ECI Biotech Expands in Worcester |
Aug
18
2010
|
SBIR and STTR Success Story for ECI Biotech |